Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.51 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.47 |
| ▸ | RARB | P10826 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RARA | P10276 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9148988 | 0.98 | HCAR2 (0.53) | HCAR2HCAR3NOTUMGPR84RARB | |
| SCHEMBL9147411 | 0.98 | HCAR2 (0.53) | HCAR2HCAR3NOTUMGPR84RARB | |
| SCHEMBL10945791 | 0.83 | GPR84 (0.44) | HCAR2HCAR3GPR84KMT2A | |
| SCHEMBL9150492 | 0.80 | GPR84 (0.45) | HCAR2GPR84 | |
| SCHEMBL9150482 | 0.80 | GPR84 (0.45) | HCAR2GPR84 | |
| SCHEMBL9152253 | 0.79 | ESR1 (0.48) | GPR84ALDH1A1MAPT | |
| SCHEMBL8705694 | 0.78 | RARB (0.44) | HCAR2HCAR3NOTUMRARBMEN1 | |
| SCHEMBL10936345 | 0.77 | HCAR2 (0.39) | HCAR2HCAR3GPR84KMT2A | |
| SCHEMBL1156268 | 0.76 | CA12 (0.45) | HCAR2HCAR3MEN1ALDH1A1KMT2A | |
| SCHEMBL9772106 | 0.74 | PLA2G4B (0.50) | GPR84KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0434940-B1 | N-oxygenated arylpyrrole, insecticidal, acaricidal and nematicidal agents | AMERICAN CYANAMID CO (US) | 1996-05-29 | — | — | EP | claimed |
| US-11833129-B2 | Thiophene compound for treatment of exfoliating glaucoma | AVOSCIENCE, LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-11058663-B2 | Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders | AVOSCIENCE, LLC (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210137876-A1 | LIPIDIC FURAN, PYRROLE, AND THIOPHENE COMPOUNDS FOR TREATMENT OF CANCER, NEUROLOGICAL DISORDERS, AND FIBROTIC DISORDERS | AVOSCIENCE, LLC (US) | 2021-05-13 | — | — | US | disclosed |
| US-20200237709-A1 | LIPIDIC FURAN, PYRROLE, AND THIOPHENE COMPOUNDS FOR TREATMENT OF CANCER, NEUROLOGICAL DISORDERS, AND FIBROTIC DISORDERS | AVOSCIENCE, LLC (US) | 2020-07-30 | — | — | US | disclosed |
| US-20180360798-A1 | Lipid Furan, Pyrrole, and Thiophene Compounds for Treatment of Cancer, Neurological Disorders, and Fibrotic Disorders | AVOSCIENCE, LLC (US) | 2018-12-20 | — | — | US | disclosed |
| US-10085962-B2 | Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders | AVOSCIENCE, LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-20180050013-A1 | LIPIDIC FURAN, PYRROLE, AND THIOPHENE COMPOUNDS FOR TREATMENT OF CANCER, NEUROLOGICAL DISORDERS, AND FIBROTIC DISORDERS | AVOSCIENCE, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-9814694-B2 | Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders | Avioscience, LLC (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160263080-A1 | LIPIDIC FURAN, PYRROLE, AND THIOPHENE COMPOUNDS FOR TREATMENT OF CANCER, NEUROLOGICAL DISORDERS, AND FIBROTIC DISORDERS | AVOSCIENCE, LLC | 2016-09-15 | — | — | US | disclosed |
| US-9371302-B2 | Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer | AVOSCIENCE, LLC (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2978422-A2 | LIPIDIC FURAN, PYRROLE, AND THIOPHENE COMPOUNDS FOR TREATMENT OF CANCER, NEUROLOGICAL DISORDERS, AND FIBROTIC DISORDERS | Avoscience, LLC (US) | 2016-02-03 | — | — | EP | disclosed |
| US-20140309274-A1 | Lipidic Furan, Pyrrole, and Thiophene Compounds for Treatment of Cancer, Neurological Disorders, and Fibrotic Disorders | AVOSCIENCE, LLC (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2014160940-A2 | LIPIDIC FURAN, PYRROLE, AND THIOPHENE COMPOUNDS FOR TREATMENT OF CANCER, NEUROLOGICAL DISORDERS, AND FIBROTIC DISORDERS | AVOSCIENCE, LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| US-4511575-A | Antidiabetic pyrrolecarboxylic acids | PFIZER INC. (US) | 1985-04-16 | — | — | US | disclosed |
| US-4511576-A | Antidiabetic pyrrolecarboxylic acids | PFIZER INC. (US) | 1985-04-16 | — | — | US | disclosed |
| US-4351843-A | LOWERING BLOOD GLUCOSE | PFIZER INC. (US) | 1982-09-28 | — | — | US | disclosed |
| US-4282242-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137876-A1 | LIPIDIC FURAN, PYRROLE, AND THIOPHENE COMPOUNDS FOR TREATMENT OF CANCER, NEUROLOGICAL DISORDERS, AND FIBROTIC DISORDERS | FAH, PHOSPHO1, FAP | HCAR2 2526/4885HCAR3 3962/4885NOTUM 673/4885 |
| US-20200237709-A1 | LIPIDIC FURAN, PYRROLE, AND THIOPHENE COMPOUNDS FOR TREATMENT OF CANCER, NEUROLOGICAL DISORDERS, AND FIBROTIC DISORDERS | FAH, PHOSPHO1, FAP | HCAR2 2526/4885HCAR3 3962/4885NOTUM 673/4885 |
| US-20140309274-A1 | Lipidic Furan, Pyrrole, and Thiophene Compounds for Treatment of Cancer, Neurological Disorders, and Fibrotic Disorders | FAH, PHOSPHO1, FAP | HCAR2 2526/4885HCAR3 3962/4885NOTUM 673/4885 |
| US-11058663-B2 | Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders | FAH, PHOSPHO1, FAP | HCAR2 2526/4885HCAR3 3962/4885NOTUM 673/4885 |
| US-10085962-B2 | Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders | FAH, PHOSPHO1, FAP | HCAR2 2526/4885HCAR3 3962/4885NOTUM 673/4885 |
| US-20180360798-A1 | Lipid Furan, Pyrrole, and Thiophene Compounds for Treatment of Cancer, Neurological Disorders, and Fibrotic Disorders | FAH, PHOSPHO1, FAP | HCAR2 2949/4885HCAR3 3734/4885NOTUM 526/4885 |
| US-20180050013-A1 | LIPIDIC FURAN, PYRROLE, AND THIOPHENE COMPOUNDS FOR TREATMENT OF CANCER, NEUROLOGICAL DISORDERS, AND FIBROTIC DISORDERS | FAH, PHOSPHO1, FAP | HCAR2 2526/4885HCAR3 3962/4885NOTUM 673/4885 |
| US-11833129-B2 | Thiophene compound for treatment of exfoliating glaucoma | TYMP, TDP1, TDP2 | HCAR2 4431/4885HCAR3 4175/4885NOTUM 2401/4885 |
| US-20160263080-A1 | LIPIDIC FURAN, PYRROLE, AND THIOPHENE COMPOUNDS FOR TREATMENT OF CANCER, NEUROLOGICAL DISORDERS, AND FIBROTIC DISORDERS | FAH, PHOSPHO1, FAP | HCAR2 2526/4885HCAR3 3962/4885NOTUM 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.